Immuneering (IMRX) Retained Earnings (2020 - 2026)

Immuneering's Retained Earnings history runs 7 years deep, the most recent figure standing at -$241005.0 for Q1 2026.

• On a quarterly basis, Retained Earnings rose 99.9% year-over-year to -$241005.0 in Q1 2026; TTM through Mar 2026 was -$241005.0, a 99.9% increase from a year earlier, with the FY2025 full-year figure at $498.7 million, up 87.71% from the prior year.
• Retained Earnings eased to -$241005.0 in Q1 2026 per IMRX's latest filing, from $498.7 million in the prior quarter.
• Across five years, Retained Earnings topped out at $498.7 million in Q4 2025 and bottomed at -$268.7 million in Q3 2025.
• The 5-year median for Retained Earnings is -$83.7 million (2022), against an average of -$43.3 million.
• Biggest YoY gain for Retained Earnings was 262.72% in 2024; the steepest drop was 35092275.3% in 2024.
• Year by year, Retained Earnings stood at $219.6 million in 2022, then tumbled by 174.33% to -$163.3 million in 2023, then soared by 262.72% to $265.7 million in 2024, then jumped by 87.71% to $498.7 million in 2025, then sank by 100.05% to -$241005.0 in 2026.
• Per Business Quant, the three latest IMRX Retained Earnings figures stand at -$241005.0 (Q1 2026), $498.7 million (Q4 2025), and -$268.7 million (Q3 2025).